Form 8-K - Current report:
SEC Accession No. 0001628280-22-025971
Filing Date
2022-10-04
Accepted
2022-10-04 16:42:39
Documents
14
Period of Report
2022-10-04
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20221004.htm   iXBRL 8-K 38663
2 EX-99.1 pipelinechart.htm EX-99.1 1703
6 pipelinechart001.jpg GRAPHIC 90987
  Complete submission text file 0001628280-22-025971.txt   311602

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20221004.xsd EX-101.SCH 1908
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20221004_lab.xml EX-101.LAB 25948
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20221004_pre.xml EX-101.PRE 13681
8 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20221004_htm.xml XML 11883
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 221292413
SIC: 2836 Biological Products, (No Diagnostic Substances)